EOLS Evolus, Inc.

8-K Current Report

Filed: March 13, 2026

Health Care

Pharmaceutical Preparations

Evolus, Inc. (EOLS) 8-K current report filed with SEC EDGAR on March 13, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 5.02: Departure/Election of Directors or Officers

AI Filing Analysis
8-K

Item 5.02 · Departure/Election of Directors or Officers

• Vikram Malik reclassified from Class III to Class II director on March 13, 2026 to rebalance Evolus's classified board after Simone Blank's departure
• Malik retains Chairman of the Board and Compensation Committee roles — no change in influence or oversight function

+3 more insights

Other Evolus, Inc. 8-K Filings

8-K Mar 3, 2026

Get deeper insights on Evolus, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.